Logo Illumina, Inc.

Illumina, Inc. (ILMN) stock: analyst price target and their real reliability

Live quote · data updated Oct 14, 2026
Illumina, Inc. · Health Care · ref. ETF XLV · 128 calls · price $271.18
🔔Price alertsCreate an alert →
What the company does: Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

📈 Illumina, Inc. (ILMN) stock price

$271.18+198.0% over range
Oct 14, 25low $91 · high $293.69Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
69% recommend buying · 13 analysts
📊 JPI status : Illumina, Inc. has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
⚠️ The stock trades above the median target: it has beaten expectations. The “Buy” reflects conviction on the company, but the remaining quantified upside is low/negative.

🎯 ILMN price target & analyst consensus — price $271

The price target · all analysts combined (13 targets)
Highest target · 1 firm of 13$310+14.3%
Median target · of 13 targets$232.5-14.3%
Lowest target · 1 firm of 13$113-58.3%
Current price$271.18
Where these 13 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 431% $300 ↔ $310
Below 969% $113 ↔ $270
⏳ Targets haven't kept up with the price. 69% of ratings say “Buy”, yet 9 of 13 targets sit below the current price: the stock has risen past what analysts were aiming for, and some haven't raised their target yet. Read it as a dated view, not as a forecast of a drop.
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Guggenheim — 77% of its targets hit on this sector (53 calls tested). It aims for $305 (+13 %), call made on October 2, 2026, maturing on October 2, 2027 (12 d ago).

The 8 reliable analysts $245-9.6 %
The 5 other firms $235-13 %
How to read it: the 8 reliable firms are not filtered by optimism — 3 aim above the price, 5 below, hence their $245 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 13 ratings (last 6 months)
Strong Buy00%
Buy969%
Hold215%
Sell215%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Illumina, Inc.? The JPI assistant answers using our backtest data.

📈 Illumina, Inc. fundamentals: valuation, margins & growth › open the full page

P/E 50.3Net margin 18.3 %Revenue growth +9.4 %High P/E

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2022
marg. -96 %
2023
Rev −2%
2024
Rev −3%
2025
Rev −1%

🔎 Detailed analyses

🏛️ Which US Congress members hold Illumina, Inc. (ILMN)?

3 Congress members have disclosed ILMN buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Donald Beyer 8× · 50%Kathy Manning 3× · 43%Michael Burgess 1× · 40%
→ Full members ranking (who beats the market)

✅ Historical analyst reliability on ILMN

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm ↕ % right i ↕ Gain vs sector i ↕ Calls i ↕
Credit Suisse 100% +119.0% 4
JMP Securities 100% +45.7% 2
Baird ↗ 100% +38.4% 3
Guggenheim ↗ 100% +33.9% 5
Leerink Swann 100% +33.4% 3
Wedbush ↗ 100% +30.0% 2
Macquarie ↗ 100% +22.0% 2
Cowen & Co. 100% +20.1% 4
UBS ↗ 75% +63.0% 4
JP Morgan ↗ 75% +17.6% 4
See the other 21 firms
OTR Global 0% -32.5% 2
HSBC ↗ 0% -31.6% 2
TD Cowen ↗ 0% -21.3% 2
Scotiabank ↗ 0% -13.9% 4
Morgan Stanley ↗ 11% -32.4% 9
Canaccord Genuity ↗ 18% -13.7% 11
RBC Capital ↗ 31% -7.1% 16
Stifel ↗ 36% -3.8% 11
Stephens & Co. ↗ 38% -1.3% 8
Piper Sandler ↗ 45% +3.6% 20
First Analysis 50% -16.8% 2
Tigress Financial ↗ 50% +4.7% 2
Wells Fargo ↗ 50% +7.5% 8
Argus Research ↗ 50% +9.1% 6
Deutsche Bank ↗ 50% +20.3% 2
Evercore ISI Group ↗ 50% +28.2% 8
Barclays ↗ 52% -1.9% 21
SVB Leerink 57% +8.5% 7
Citigroup ↗ 60% +9.7% 15
BTIG ↗ 67% -8.6% 3
B of A Securities ↗ 67% +29.4% 9

📊 What $1,000 invested in Illumina, Inc. would be worth › open the full page

In short — $1,000 invested in Illumina, Inc. 10 years ago would be worth $942 today, i.e. -1%/yr on average. Best year: 2017 (+71%), worst: 2022 (-47%). Price performance, excluding dividends.

If I'd invested $1,000 in Illumina, Inc.

InvestmentWorth todayGain
1 years ago$1,316+32%
3 years ago$894-11%
5 years ago$489-51%
→ See Illumina, Inc.'s full return history + gain calculator

Return by year (Illumina, Inc.)

YearReturn$1,000 invested at year start
2026 (YTD)+34%$1,341 (+34%)
2025-2%$1,316 (+32%)
2024-1%$1,298 (+30%)
→ See Illumina, Inc.'s full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Illumina, Inc.

Loading news…

📋 All analyst calls on ILMN

TD Cowen ↗
Oct 13, 26
■ Hold neutral · not a buy · 🎯$270
Today : $271.18 — gap to target -0%
🎯 on ILMN : no call matured yet · 📊 on Health : 55.6% · +19.8% (27 calls)
in progress (365j)
matures : Oct 13, 27
Barclays ↗
Oct 7, 26
▼ Underweight · 🎯$200
Price at call : $264.57 — upside -24%
Today : $271.18 — upside -26%
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Oct 7, 27
RBC Capital ↗
Oct 5, 26
▲ Outperform · 🎯$310
Price at call : $293.69 — upside +6%
Today : $271.18 — upside +14%
🎯 on ILMN : 42% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Oct 5, 27
Guggenheim ↗
Oct 1, 26
▲ Buy · 🎯$305
Price at call : $273.04 — upside +12%
Today : $271.18 — upside +12%
🎯 on ILMN : 100% (5 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
in progress (365j)
matures : Oct 1, 27
▲ Outperform · 🎯$300
Price at call : $273.68 — upside +10%
Today : $271.18 — upside +11%
🎯 on ILMN : 0% (1 call matured) · 📊 on Health : 58.3% · +20.9% (12 calls)
in progress (365j)
matures : Sep 29, 27
Piper Sandler ↗
Sep 28, 26
▲ Overweight · 🎯$305
Price at call : $272 — upside +12%
Today : $271.18 — upside +12%
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Sep 28, 27
UBS ↗
Sep 9, 26
▲ Buy · 🎯$260
Price at call : $205 — upside +27%
Today : $271.18 — upside -4%
🎯 on ILMN : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : Sep 9, 27
▲ Buy · 🎯$235
Price at call : $221.66 — upside +6%
Today : $271.18 — upside -13%
🎯 on ILMN : 50% (6 calls matureds) · 📊 on Health : 41.7% · +1.1% (12 calls)
in progress (365j)
matures : Sep 3, 27
See the other 120 calls, newest to oldest
■ Hold neutral · not a buy · 🎯$205
Price at call : $203.01 — gap to target +1%
Today : $271.18 — gap to target -24%
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
in progress (365j)
matures : Aug 3, 27
Citigroup ↗
Aug 3, 26
▼ Sell · 🎯$113
Price at call : $203.01 — upside -44%
Today : $271.18 — upside -58%
🎯 on ILMN : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Aug 3, 27
Piper Sandler ↗
Aug 3, 26
▲ Overweight · 🎯$225
Price at call : $203.01 — upside +11%
Today : $271.18 — upside -17%
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Aug 3, 27
RBC Capital ↗
Jul 31, 26
▲ Outperform · 🎯$230
Price at call : $198.16 — upside +16%
Today : $271.18 — upside -15%
🎯 on ILMN : 42% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Jul 31, 27
JP Morgan ↗
Jul 31, 26
▲ Overweight · 🎯$230
Price at call : $198.16 — upside +16%
Today : $271.18 — upside -15%
🎯 on ILMN : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Jul 31, 27
TD Cowen ↗
Jul 31, 26
■ Hold neutral · not a buy · 🎯$210
Price at call : $198.16 — gap to target +6%
Today : $271.18 — gap to target -23%
🎯 on ILMN : no call matured yet · 📊 on Health : 55.6% · +19.8% (27 calls)
in progress (365j)
matures : Jul 31, 27
Guggenheim ↗
Jul 31, 26
▲ Buy · 🎯$226
Price at call : $198.16 — upside +14%
Today : $271.18 — upside -17%
🎯 on ILMN : 100% (5 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
in progress (365j)
matures : Jul 31, 27
Stifel ↗
Jul 31, 26
▲ Buy · 🎯$225
Price at call : $198.16 — upside +14%
Today : $271.18 — upside -17%
🎯 on ILMN : no call matured yet · 📊 on Health : 48% · +12.3% (100 calls)
in progress (365j)
matures : Jul 31, 27
Barclays ↗
Jul 31, 26
▼ Underweight · 🎯$160
Price at call : $205.1 — upside -22%
Today : $271.18 — upside -41%
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Jul 31, 27
▲ Outperform · 🎯$210
Price at call : $184.68 — upside +14%
Today : $271.18 — upside -23%
🎯 on ILMN : 0% (1 call matured) · 📊 on Health : 58.3% · +20.9% (12 calls)
in progress (365j)
matures : Jul 17, 27
■ Hold neutral · not a buy · 🎯$190
Price at call : $191.2 — gap to target -1%
Today : $271.18 — gap to target -30%
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
in progress (365j)
matures : Jul 14, 27
▲ Outperform · 🎯$200
Price at call : $191.76 — upside +4%
Today : $271.18 — upside -26%
🎯 on ILMN : 50% (8 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
in progress (365j)
matures : Jul 6, 27
Piper Sandler ↗
Jul 1, 26
▲ Overweight · 🎯$200
Price at call : $183.89 — upside +9%
Today : $271.18 — upside -26%
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Jul 1, 27
Guggenheim ↗
Jun 29, 26
▲ Buy · 🎯$200
Price at call : $175.83 — upside +14%
Today : $271.18 — upside -26%
🎯 on ILMN : 100% (5 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
in progress (365j)
matures : Jun 29, 27
Barclays ↗
Jun 24, 26
▼ Underweight · 🎯$145
Price at call : $177.65 — upside -18%
Today : $271.18 — upside -47%
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Jun 24, 27
JP Morgan ↗
Jun 10, 26
▲ Overweight · 🎯$185
Price at call : $162.47 — upside +14%
Today : $271.18 — upside -32%
🎯 on ILMN : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Jun 10, 27
Guggenheim ↗
Jun 1, 26
▲ Buy · 🎯$180
Price at call : $164.4 — upside +9%
Today : $271.18 — upside -34%
🎯 on ILMN : 100% (5 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
in progress (365j)
matures : Jun 1, 27
Citigroup ↗
May 4, 26
▼ Sell · 🎯$95
Price at call : $139.07 — upside -32%
Today : $271.18 — upside -65%
🎯 on ILMN : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : May 4, 27
■ Hold neutral · not a buy · 🎯$140
Price at call : $139.37 — gap to target +0%
Today : $271.18 — gap to target -48%
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
in progress (365j)
matures : May 2, 27
JP Morgan ↗
May 1, 26
■ Neutral neutral · not a buy · 🎯$125
Price at call : $139.37 — gap to target -10%
Today : $271.18 — gap to target -54%
🎯 on ILMN : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : May 1, 27
Barclays ↗
May 1, 26
▼ Underweight · 🎯$122
Price at call : $139.37 — upside -12%
Today : $271.18 — upside -55%
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : May 1, 27
▲ Outperform · 🎯$155
Price at call : $135.78 — upside +14%
Today : $271.18 — upside -43%
🎯 on ILMN : 50% (8 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
in progress (365j)
matures : May 1, 27
Piper Sandler ↗
Feb 9, 26
▲ Overweight · 🎯$170
Price at call : $119.32 — upside +42%
Today : $271.18 — upside -37%
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Feb 9, 27
JP Morgan ↗
Feb 6, 26
■ Neutral neutral · not a buy · 🎯$120
Price at call : $117.25 — gap to target +2%
Today : $271.18 — gap to target -56%
🎯 on ILMN : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Feb 6, 27
Guggenheim ↗
Jan 26, 26
▲ Buy · 🎯$170
Price at call : $152.09 — upside +12%
Today : $271.18 — upside -37%
🎯 on ILMN : 100% (5 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
in progress (365j)
matures : Jan 26, 27
■ Hold neutral · not a buy · 🎯$150
Price at call : $153 — gap to target -2%
Today : $271.18 — gap to target -45%
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
in progress (365j)
matures : Jan 26, 27
Stifel ↗
Jan 20, 26
▲ Buy · 🎯$155
Price at call : $152.48 — upside +2%
Today : $271.18 — upside -43%
🎯 on ILMN : no call matured yet · 📊 on Health : 48% · +12.3% (100 calls)
in progress (365j)
matures : Jan 20, 27
TD Cowen ↗
Jan 7, 26
■ Hold neutral · not a buy · 🎯$140
Price at call : $145.83 — gap to target -4%
Today : $271.18 — gap to target -48%
🎯 on ILMN : no call matured yet · 📊 on Health : 55.6% · +19.8% (27 calls)
in progress (365j)
matures : Jan 7, 27
Guggenheim ↗
Jan 5, 26
▲ Buy · 🎯$144
Price at call : $147.11 — upside -2%
Today : $271.18 — upside -47%
🎯 on ILMN : 100% (5 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
in progress (365j)
matures : Jan 5, 27
■ Hold neutral · not a buy · 🎯$130
Price at call : $137.6 — gap to target -6%
Today : $271.18 — gap to target -52%
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
in progress (365j)
matures : Dec 22, 26
Barclays ↗
Dec 15, 25
▼ Underweight · 🎯$110
Price at call : $131.56 — upside -16%
Today : $271.18 — upside -59%
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Dec 15, 26
JP Morgan ↗
Dec 15, 25
■ Neutral neutral · not a buy · 🎯$130
Price at call : $131.56 — gap to target -1%
Today : $271.18 — gap to target -52%
🎯 on ILMN : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Dec 15, 26
Barclays ↗
Oct 31, 25
▼ Underweight · 🎯$100
Price at call : $119.99 — upside -17%
Today : $271.18 — upside -63%
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Oct 31, 26
■ Hold neutral · not a buy · 🎯$112
Price at call : $119.99 — gap to target -7%
Today : $271.18 — gap to target -59%
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
in progress (365j)
matures : Oct 31, 26
JP Morgan ↗
Oct 31, 25
■ Neutral neutral · not a buy · 🎯$105
Price at call : $119.99 — gap to target -12%
Today : $271.18 — gap to target -61%
🎯 on ILMN : no call matured yet · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Oct 31, 26
TD Cowen ↗
Oct 31, 25
■ Hold neutral · not a buy · 🎯$115
Price at call : $119.99 — gap to target -4%
Today : $271.18 — gap to target -58%
🎯 on ILMN : no call matured yet · 📊 on Health : 55.6% · +19.8% (27 calls)
in progress (365j)
matures : Oct 31, 26
UBS ↗
Oct 31, 25
■ Neutral neutral · not a buy · 🎯$120
Price at call : $119.99 — gap to target +0%
Today : $271.18 — gap to target -56%
🎯 on ILMN : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : Oct 31, 26
Baird ↗
Oct 31, 25
■ Neutral neutral · not a buy · 🎯$109
Price at call : $119.99 — gap to target -9%
Today : $271.18 — gap to target -60%
🎯 on ILMN : no call matured yet · 📊 on Health : 48.1% · +0.7% (77 calls)
in progress (365j)
matures : Oct 31, 26
▲ Outperform · 🎯$142
Price at call : $123.54 — upside +15%
Today : $271.18 — upside -48%
🎯 on ILMN : 50% (8 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
in progress (365j)
matures : Oct 31, 26
▲ Outperform · 🎯$132
Price at call : $97.78 — upside +35%
Today : $271.18 — upside -51%
Expected +35% · Actual +171% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 50% (8 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
+170.6%
stock +171% · XLV +16%
matured Oct 7, 26
Barclays ↗
Oct 2, 25
▼ Underweight · 🎯$95
Price at call : $102.12 — upside -7%
Today : $271.18 — upside -65%
Expected -7% · Actual +188% · Reason (≤ −15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
-187.6%
stock +188% · XLV +16%
matured Oct 2, 26
■ Equal-Weight neutral · not a buy · 🎯$105
Price at call : $97.76 — gap to target +7%
Today : $271.18 — gap to target -61%
🎯 on ILMN : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : Aug 4, 26
RBC Capital ↗
Aug 1, 25
▲ Outperform · 🎯$126
Price at call : $98.44 — upside +28%
Today : $271.18 — upside -54%
Expected +28% · Actual +101% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 42% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+101.3%
stock +101% · XLV +22%
matured Aug 1, 26
Barclays ↗
Aug 1, 25
▼ Underweight · 🎯$90
Price at call : $94.66 — upside -5%
Today : $271.18 — upside -67%
Expected -5% · Actual +109% · Reason (≤ −15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
-109.3%
stock +109% · XLV +24%
matured Aug 1, 26
▲ Outperform · 🎯$128
Price at call : $99.27 — upside +29%
Today : $271.18 — upside -53%
Expected +29% · Actual +89% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 50% (8 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
+89.2%
stock +89% · XLV +20%
matured Jul 8, 26
Barclays ↗
Jun 24, 25
▼ Underweight · 🎯$85
Price at call : $93.23 — upside -9%
Today : $271.18 — upside -69%
Expected -9% · Actual +91% · Reason (≤ −15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
-90.5%
stock +91% · XLV +16%
matured Jun 24, 26
Stephens & Co. ↗
May 20, 25
▲ Overweight · 🎯$105
Price at call : $84.21 — upside +25%
Today : $271.18 — upside -61%
Expected +25% · Actual +69% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 38% (8 calls matureds) · 📊 on Health : 64.1% · +10.3% (39 calls)
+68.5%
stock +69% · XLV +9%
matured May 20, 26
Piper Sandler ↗
May 15, 25
▲ Overweight · 🎯$185
Price at call : $83.62 — upside +121%
Today : $271.18 — upside -32%
Expected +121% · Actual +69% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
+69.2%
stock +69% · XLV +9%
matured May 15, 26
Guggenheim ↗
May 9, 25
▲ Buy · 🎯$114
Price at call : $81.57 — upside +40%
Today : $271.18 — upside -58%
Expected +40% · Actual +75% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 100% (5 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
+74.7%
stock +75% · XLV +5%
matured May 9, 26
Barclays ↗
Apr 10, 25
▼ Underweight · 🎯$77
Price at call : $74.78 — upside +3%
Today : $271.18 — upside -72%
Expected +3% · Actual +70% · Reason (≤ −15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
-69.8%
stock +70% · XLV +8%
matured Apr 10, 26
RBC Capital ↗
Apr 8, 25
▲ Outperform · 🎯$112
Price at call : $76.3 — upside +47%
Today : $271.18 — upside -59%
Expected +47% · Actual +62% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 42% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+62.1%
stock +62% · XLV +8%
matured Apr 8, 26
RBC Capital ↗
Mar 12, 25
▲ Outperform · 🎯$128
Price at call : $84.05 — upside +52%
Today : $271.18 — upside -53%
Expected +52% · Actual +42% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 42% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+41.5%
stock +42% · XLV +4%
matured Mar 12, 26
Stephens & Co. ↗
Mar 11, 25
▲ Overweight · 🎯$156
Price at call : $84.2 — upside +85%
Today : $271.18 — upside -42%
Expected +85% · Actual +37% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 38% (8 calls matureds) · 📊 on Health : 64.1% · +10.3% (39 calls)
+37.2%
stock +37% · XLV +4%
matured Mar 11, 26
Piper Sandler ↗
Feb 10, 25
▲ Overweight · 🎯$190
Price at call : $100.68 — upside +89%
Today : $271.18 — upside -30%
Expected +89% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
+15.6%
stock +16% · XLV +7%
matured Feb 10, 26
Barclays ↗
Feb 10, 25
▼ Underweight · 🎯$100
Price at call : $104.99 — upside -5%
Today : $271.18 — upside -63%
Expected -5% · Actual +14% · Reason (≤ −15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
-13.7%
stock +14% · XLV +6%
matured Feb 10, 26
RBC Capital ↗
Feb 7, 25
▲ Outperform · 🎯$247
Price at call : $104.99 — upside +135%
Today : $271.18 — upside -9%
Expected +135% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 42% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+11.7%
stock +12% · XLV +7%
matured Feb 7, 26
Guggenheim ↗
Feb 7, 25
▲ Buy · 🎯$150
Price at call : $104.99 — upside +43%
Today : $271.18 — upside -45%
Expected +43% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 100% (5 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
+11.7%
stock +12% · XLV +7%
matured Feb 7, 26
Stephens & Co. ↗
Nov 12, 24
▲ Overweight · 🎯$184
Price at call : $147.62 — upside +25%
Today : $271.18 — upside -32%
Expected +25% · Actual -17% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 38% (8 calls matureds) · 📊 on Health : 64.1% · +10.3% (39 calls)
-17.4%
stock -17% · XLV +4%
matured Nov 12, 25
Piper Sandler ↗
Nov 11, 24
▲ Overweight · 🎯$185
Price at call : $151.5 — upside +22%
Today : $271.18 — upside -32%
Expected +22% · Actual -19% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
-19.1%
stock -19% · XLV +1%
matured Nov 11, 25
RBC Capital ↗
Nov 5, 24
▲ Outperform · 🎯$254
Price at call : $151.83 — upside +67%
Today : $271.18 — upside -6%
Expected +67% · Actual -20% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 42% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-20.2%
stock -20% · XLV -1%
matured Nov 5, 25
▲ Outperform · 🎯$200
Price at call : $146.07 — upside +37%
Today : $271.18 — upside -26%
Expected +37% · Actual -32% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 0% (1 call matured) · 📊 on Health : 58.3% · +20.9% (12 calls)
-31.9%
stock -32% · XLV -5%
matured Oct 17, 25
HSBC ↗
Oct 17, 24
▲ Buy · 🎯$180
Price at call : $143.52 — upside +25%
Today : $271.18 — upside -34%
Expected +25% · Actual -33% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 0% (2 calls matureds) · 📊 on Health : 50% · +7.0% (4 calls)
-33.5%
stock -33% · XLV -6%
matured Oct 17, 25
RBC Capital ↗
Oct 10, 24
▲ Outperform · 🎯$252
Price at call : $145.54 — upside +73%
Today : $271.18 — upside -7%
Expected +73% · Actual -35% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 42% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-34.7%
stock -35% · XLV -8%
matured Oct 10, 25
Argus Research ↗
Aug 28, 24
▲ Buy · 🎯$150
Price at call : $131.7 — upside +14%
Today : $271.18 — upside -45%
Expected +14% · Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 50% (6 calls matureds) · 📊 on Health : 41.7% · +1.1% (12 calls)
-24.7%
stock -25% · XLV -12%
matured Aug 28, 25
RBC Capital ↗
Aug 14, 24
▲ Outperform · 🎯$242
Price at call : $128.8 — upside +88%
Today : $271.18 — upside -11%
Expected +88% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 42% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-22.3%
stock -22% · XLV -11%
matured Aug 14, 25
Piper Sandler ↗
Aug 13, 24
▲ Overweight · 🎯$195
Price at call : $119.72 — upside +63%
Today : $271.18 — upside -28%
Expected +63% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
-15.5%
stock -16% · XLV -12%
matured Aug 13, 25
RBC Capital ↗
Aug 7, 24
▲ Outperform · 🎯$242
Price at call : $126.7 — upside +91%
Today : $271.18 — upside -11%
Expected +91% · Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 42% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-25.4%
stock -25% · XLV -13%
matured Aug 7, 25
Stephens & Co. ↗
Jul 10, 24
▲ Overweight · 🎯$170
Price at call : $113.17 — upside +50%
Today : $271.18 — upside -37%
Expected +50% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 38% (8 calls matureds) · 📊 on Health : 64.1% · +10.3% (39 calls)
-11.6%
stock -12% · XLV -7%
matured Jul 10, 25
RBC Capital ↗
Jul 1, 24
▲ Outperform · 🎯$242
Price at call : $105.51 — upside +129%
Today : $271.18 — upside -11%
Expected +129% · Actual -5% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 42% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-4.9%
stock -5% · XLV -6%
matured Jul 1, 25
▲ Outperform · 🎯$175
Price at call : $109.52 — upside +60%
Today : $271.18 — upside -35%
Expected +60% · Actual -20% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 50% (8 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
-20.1%
stock -20% · XLV -7%
matured Jun 11, 25
▲ Overweight · 🎯$170
Price at call : $107.61 — upside +58%
Today : $271.18 — upside -37%
Expected +58% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 38% (8 calls matureds) · 📊 on Health : 64.1% · +10.3% (39 calls)
-26.1%
stock -26% · XLV -6%
matured May 7, 25
Barclays ↗
Apr 10, 24
▼ Underweight · 🎯$100
Price at call : $127.14 — upside -21%
Today : $271.18 — upside -63%
Expected -21% · Actual -41% · Reason (≤ −15%) : ✓ Yes
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
+41.2%
stock -41% · XLV -3%
matured Apr 10, 25
Stephens & Co. ↗
Apr 10, 24
▲ Overweight · 🎯$170
Price at call : $127.6 — upside +33%
Today : $271.18 — upside -37%
Expected +33% · Actual -44% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 38% (8 calls matureds) · 📊 on Health : 64.1% · +10.3% (39 calls)
-44.1%
stock -44% · XLV -5%
matured Apr 10, 25
RBC Capital ↗
Apr 9, 24
▲ Outperform · 🎯$253
Price at call : $127.6 — upside +98%
Today : $271.18 — upside -7%
Expected +98% · Actual -44% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 42% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-44.1%
stock -44% · XLV -5%
matured Apr 9, 25
Stephens & Co. ↗
Feb 14, 24
▲ Overweight · 🎯$170
Price at call : $142.09 — upside +20%
Today : $271.18 — upside -37%
Expected +20% · Actual -29% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 38% (8 calls matureds) · 📊 on Health : 64.1% · +10.3% (39 calls)
-29.4%
stock -29% · XLV -0%
matured Feb 13, 25
RBC Capital ↗
Feb 9, 24
▲ Outperform · 🎯$258
Price at call : $136.15 — upside +89%
Today : $271.18 — upside -5%
Expected +89% · Actual -23% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 42% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-22.9%
stock -23% · XLV +1%
matured Feb 8, 25
Barclays ↗
Jan 25, 24
▼ Underweight · 🎯$80
Price at call : $136.8 — upside -42%
Today : $271.18 — upside -70%
Expected -42% · Actual +1% · Reason (≤ −15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
-0.9%
stock +1% · XLV +6%
matured Jan 24, 25
RBC Capital ↗
Dec 19, 23
▲ Outperform · 🎯$258
Price at call : $133.17 — upside +94%
Today : $271.18 — upside -5%
Expected +94% · Actual +1% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 42% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+0.6%
stock +1% · XLV +3%
matured Dec 18, 24
Guggenheim ↗
Dec 14, 23
▲ Buy · 🎯$155
Price at call : $127.91 — upside +21%
Today : $271.18 — upside -43%
Expected +21% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 100% (5 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
+12.5%
stock +12% · XLV +4%
matured Dec 13, 24
Stephens & Co. ↗
Dec 14, 23
▲ Overweight · 🎯$170
Price at call : $127.91 — upside +33%
Today : $271.18 — upside -37%
Expected +33% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 38% (8 calls matureds) · 📊 on Health : 64.1% · +10.3% (39 calls)
+12.5%
stock +12% · XLV +4%
matured Dec 13, 24
Piper Sandler ↗
Nov 13, 23
▲ Overweight · 🎯$190
Price at call : $94.83 — upside +100%
Today : $271.18 — upside -30%
Expected +100% · Actual +54% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
+54.1%
stock +54% · XLV +15%
matured Nov 12, 24
Piper Sandler ↗
Oct 16, 23
▲ Overweight · 🎯$200
Price at call : $128.28 — upside +56%
Today : $271.18 — upside -26%
Expected +56% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
+12.2%
stock +12% · XLV +17%
matured Oct 15, 24
Barclays ↗
Sep 29, 23
▼ Underweight · 🎯$100
Price at call : $133.54 — upside -25%
Today : $271.18 — upside -63%
Expected -25% · Actual -2% · Reason (≤ −15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
+2.3%
stock -2% · XLV +20%
matured Sep 28, 24
▲ Outperform · 🎯$240
Price at call : $155.09 — upside +55%
Today : $271.18 — upside -11%
Expected +55% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 50% (8 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
-16.0%
stock -16% · XLV +19%
matured Aug 31, 24
▲ Buy · 🎯$285
Price at call : $165.09 — upside +73%
Today : $271.18 — upside +5%
Expected +73% · Actual -21% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
-21.1%
stock -21% · XLV +15%
matured Aug 15, 24
Piper Sandler ↗
Aug 15, 23
▲ Overweight · 🎯$275
Price at call : $164.92 — upside +67%
Today : $271.18 — upside +1%
Expected +67% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
-21.9%
stock -22% · XLV +14%
matured Aug 14, 24
HSBC ↗
Aug 14, 23
▲ Buy · 🎯$235
Price at call : $170.37 — upside +38%
Today : $271.18 — upside -13%
Expected +38% · Actual -30% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 0% (2 calls matureds) · 📊 on Health : 50% · +7.0% (4 calls)
-29.7%
stock -30% · XLV +11%
matured Aug 13, 24
▲ Outperform · 🎯$240
Price at call : $180.08 — upside +33%
Today : $271.18 — upside -11%
Expected +33% · Actual -31% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 50% (8 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
-31.4%
stock -31% · XLV +11%
matured Aug 9, 24
▲ Buy · 🎯$300
Price at call : $177.51 — upside +69%
Today : $271.18 — upside +11%
Expected +69% · Actual -39% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
-38.9%
stock -39% · XLV +11%
matured Jul 5, 24
▲ Buy · 🎯$300
Price at call : $202.47 — upside +48%
Today : $271.18 — upside +11%
Expected +48% · Actual -46% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
-45.9%
stock -46% · XLV +12%
matured Jun 11, 24
Piper Sandler ↗
Feb 8, 23
▲ Overweight · 🎯$290
Price at call : $193.09 — upside +50%
Today : $271.18 — upside +7%
Expected +50% · Actual -28% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
-27.8%
stock -28% · XLV +9%
matured Feb 8, 24
Barclays ↗
Feb 8, 23
▼ Underweight · 🎯$150
Price at call : $193.09 — upside -22%
Today : $271.18 — upside -45%
Expected -22% · Actual -28% · Reason (≤ −15%) : ✓ Yes
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
+27.8%
stock -28% · XLV +9%
matured Feb 8, 24
▲ Buy · 🎯$300
Price at call : $200.82 — upside +49%
Today : $271.18 — upside +11%
Expected +49% · Actual -35% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
-35.3%
stock -35% · XLV +3%
matured Jan 17, 24
Piper Sandler ↗
Nov 14, 22
▲ Overweight · 🎯$300
Price at call : $228.18 — upside +31%
Today : $271.18 — upside +11%
Expected +31% · Actual -58% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
-58.4%
stock -58% · XLV -4%
matured Nov 14, 23
Barclays ↗
Sep 30, 22
▼ Underweight · 🎯$175
Price at call : $185.59 — upside -6%
Today : $271.18 — upside -35%
Expected -6% · Actual -28% · Reason (≤ −15%) : ✓ Yes
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
+28.5%
stock -28% · XLV +6%
matured Sep 30, 23
▲ Outperform · 🎯$250
Price at call : $195.81 — upside +28%
Today : $271.18 — upside -8%
Expected +28% · Actual -34% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 50% (8 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
-34.3%
stock -34% · XLV +5%
matured Sep 28, 23
Piper Sandler ↗
Aug 12, 22
▲ Overweight · 🎯$320
Price at call : $220.42 — upside +45%
Today : $271.18 — upside +18%
Expected +45% · Actual -23% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
-22.7%
stock -23% · XLV +1%
matured Aug 12, 23
Barclays ↗
Jul 14, 22
▼ Underweight · 🎯$150
Price at call : $172.4 — upside -13%
Today : $271.18 — upside -45%
Expected -13% · Actual +6% · Reason (≤ −15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
-5.6%
stock +6% · XLV +4%
matured Jul 14, 23
Barclays ↗
Jul 13, 22
▼ Underweight · 🎯$150
Price at call : $176.25 — upside -15%
Today : $271.18 — upside -45%
Expected -15% · Actual +4% · Reason (≤ −15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
-4.2%
stock +4% · XLV +2%
matured Jul 13, 23
Piper Sandler ↗
May 16, 22
▲ Overweight · 🎯$360
Price at call : $227.37 — upside +58%
Today : $271.18 — upside +33%
Expected +58% · Actual -14% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
-13.6%
stock -14% · XLV +1%
matured May 16, 23
Piper Sandler ↗
Feb 15, 22
▲ Overweight · 🎯$460
Price at call : $332.8 — upside +38%
Today : $271.18 — upside +70%
Expected +38% · Actual -37% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 33% (12 calls matureds) · 📊 on Health : 42.5% · +4.1% (120 calls)
-37.4%
stock -37% · XLV +1%
matured Feb 15, 23
▲ Buy · 🎯$470
Price at call : $389.04 — upside +21%
Today : $271.18 — upside +73%
Expected +21% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
-25.8%
stock -26% · XLV +7%
matured Apr 28, 22
▲ Buy · 🎯$460
Price at call : $403.54 — upside +14%
Today : $271.18 — upside +70%
Expected +14% · Actual -14% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
-13.6%
stock -14% · XLV +19%
matured Apr 6, 22
▲ Buy · 🎯$445
Price at call : $373.6 — upside +19%
Today : $271.18 — upside +64%
Expected +19% · Actual -9% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
-9.0%
stock -9% · XLV +17%
matured Mar 31, 22
Guggenheim ↗
Sep 21, 20
▲ Buy · 🎯$345
Price at call : $262.77 — upside +31%
Today : $271.18 — upside +27%
Expected +31% · Actual +61% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 100% (5 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
+60.9%
stock +61% · XLV +27%
matured Sep 21, 21
Guggenheim ↗
Oct 25, 19
▲ Buy · 🎯$350
Price at call : $282.72 — upside +24%
Today : $271.18 — upside +29%
Expected +24% · Actual +10% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 100% (5 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
+9.8%
stock +10% · XLV +16%
matured Oct 24, 20
Argus Research ↗
Sep 25, 19
▲ Buy · 🎯$340
Price at call : $291.97 — upside +16%
Today : $271.18 — upside +25%
Expected +16% · Actual -5% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 50% (6 calls matureds) · 📊 on Health : 41.7% · +1.1% (12 calls)
-4.6%
stock -5% · XLV +12%
matured Sep 24, 20
Argus Research ↗
Aug 10, 18
▲ Buy · 🎯$372
Price at call : $321.25 — upside +16%
Today : $271.18 — upside +37%
Expected +16% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 50% (6 calls matureds) · 📊 on Health : 41.7% · +1.1% (12 calls)
-12.1%
stock -12% · XLV +1%
matured Aug 10, 19
▲ Buy · 🎯$340
Price at call : $315.53 — upside +8%
Today : $271.18 — upside +25%
Expected +8% · Actual -8% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
-7.7%
stock -8% · XLV +2%
matured Jul 31, 19
▲ Buy · 🎯$290
Price at call : $259.07 — upside +12%
Today : $271.18 — upside +7%
Expected +12% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
+15.8%
stock +16% · XLV +7%
matured May 29, 19
▲ Outperform · 🎯$250
Price at call : $226.64 — upside +10%
Today : $271.18 — upside -8%
Expected +10% · Actual +30% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 50% (8 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
+29.9%
stock +30% · XLV +2%
matured Jan 4, 19
Argus Research ↗
Sep 13, 17
▲ Buy · 🎯$235
Price at call : $205.29 — upside +14%
Today : $271.18 — upside -13%
Expected +14% · Actual +67% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 50% (6 calls matureds) · 📊 on Health : 41.7% · +1.1% (12 calls)
+67.3%
stock +67% · XLV +12%
matured Sep 13, 18
▲ Buy · 🎯$215
Price at call : $194.14 — upside +11%
Today : $271.18 — upside -21%
Expected +11% · Actual +69% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
+68.9%
stock +69% · XLV +13%
matured Aug 7, 18
▲ Buy
Actual +38% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 50% (8 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
+37.7%
stock +38% · XLV +14%
matured Feb 27, 18
▲ Buy
Actual +19% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 50% (6 calls matureds) · 📊 on Health : 41.7% · +1.1% (12 calls)
+18.7%
stock +19% · XLV +6%
matured Aug 8, 17
Argus Research ↗
Mar 30, 16
▲ Buy
Actual +10% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 50% (6 calls matureds) · 📊 on Health : 41.7% · +1.1% (12 calls)
+10.0%
stock +10% · XLV +10%
matured Mar 30, 17
▲ Buy · 🎯$275
Price at call : $233.23 — upside +18%
Today : $271.18 — upside +1%
Expected +18% · Actual -38% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 18% (11 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
-37.6%
stock -38% · XLV -4%
matured Jul 16, 16
▲ Strong Buy
Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on ILMN : 50% (2 calls matureds) · 📊 on Health : 66.7% · +47.5% (6 calls)
-24.5%
stock -25% · XLV -4%
matured Apr 22, 16
▲ Buy
Actual +34% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 50% (2 calls matureds) · 📊 on Health : 66.7% · +47.5% (6 calls)
+34.0%
stock +34% · XLV +25%
matured Aug 1, 15
Maxim Group
Apr 23, 14
▲ Buy · 🎯$205
Price at call : $149.5 — upside +37%
Today : $271.18 — upside -24%
Expected +37% · Actual +25% · Reason (≥ +15%) : ✓ Yes
🎯 on ILMN : 100% (1 call matured) · 📊 on Health : 0% · -39.1% (4 calls)
+25.3%
stock +25% · XLV +29%
matured Apr 23, 15

Frequently asked questions

Should I buy Illumina, Inc. stock?

This isn't buy advice. For Illumina, Inc., the analyst consensus is "Buy", with an average price target of $233 (-14% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (4 calls tracked on Illumina, Inc.). We show the numbers — you decide.

Is it too late to buy Illumina, Inc.? How high can it go?

The most bullish analyst target on Illumina, Inc. is $310 (+14% above today's price); the average is $233. That's the upside they see. Check how reliable those analysts have actually been on Illumina, Inc. on our site before trusting it.

Is Illumina, Inc. still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 31 analysts have a real record on Illumina, Inc., the best hitting 100% over 4 calls. Current consensus: "Buy". Make your call on data, not noise.

Should you invest in Illumina, Inc.? The case for and against

The arguments for and against, one by one, from the numbers: why invest in ILMN (and why hesitate).

What has Illumina, Inc.'s past performance been?

Historical returns and a "how much if I had invested" calculator: ILMN performance & returns.

What is the best month to buy ILMN?

The 12 months ranked by the stock's past returns: best & worst month to buy ILMN.

Are insiders buying ILMN stock?

Executives' and large holders' buys and sells, decoded: insider buying on ILMN.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)